Filing Analysis
Pliant Therapeutics, Inc. filed an 8-K to furnish its second quarter 2026 financial results press release. The filing is a routine disclosure of quarterly earnings and does not contain substantive material changes or adverse events in the text provided.
📋 Key Facts
- Report date: August 11, 2026
- Reporting period: Second quarter ended June 30, 2026
- The filing is primarily used to furnish Exhibit 99.1 (Press Release) regarding financial results.
- Signed by Keith Cummings, M.D., MBA, Chief Financial Officer.
Pliant Therapeutics, Inc. announced the expansion of its Board of Directors from seven to nine members. The company appointed Dr. Robert Iannone and Dr. Flavia Borellini as new independent directors, with both joining committee roles.
📋 Key Facts
- Board size increased from 7 to 9 members effective July 9, 2026.
- Appointed Robert Iannone, M.D., M.S.C.E. as a Class I director and member of the R&D Committee.
- Appointed Flavia Borellini, Ph.D. as a Class II director and chairperson of the R&D Committee.
- New directors will receive annual retainers: $40,000 base each; Dr. Iannone an additional $7,500 for R&D committee service; Dr. Borellini an additional $15,000 for R&D chair role.
- Each new director received options to purchase 60,000 shares of common stock, vesting monthly over three years.
Pliant Therapeutics reported the results of its 2026 Annual Meeting of Stockholders held on June 11, 2026. Stockholders approved the election of Class III directors, the non-binding advisory compensation of named executive officers, and the ratification of Deloitte & Touche LLP as the independent auditor.
🚩 Red Flags
- Significant dissent in executive compensation vote: nearly 48% of votes cast (excluding abstentions) were against the advisory compensation proposal.
📋 Key Facts
- Annual Meeting held on June 11, 2026.
- 61,914,664 shares of common stock were outstanding and entitled to vote as of the April 15, 2026 record date.
- Class III directors Bernard Coulie, Gayle Crowell, and Steve Krognes were elected to serve until the 2029 Annual Meeting.
- Executive compensation was approved on a non-binding advisory basis (15,282,788 For vs 14,572,455 Against).
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Pliant Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2026. The disclosure was made via a press release furnished with the filing.
📋 Key Facts
- The filing reports financial results for the first quarter ended March 31, 2026.
- The report was filed on May 11, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the results was furnished as Exhibit 99.1.
Pliant Therapeutics announced the simultaneous retirement of three board directors and a comprehensive repricing of all underwater stock options for employees and executive officers. The options were repriced to $1.33 per share, reflecting a significant decline in the company's market valuation, and are subject to 12-18 month retention periods.
🚩 Red Flags
- Simultaneous departure of three board members (Pyott, Knobil, and Bruhn) suggests a significant governance shift.
- Broad option repricing including the CEO and CFO indicates a severe and sustained decline in stock price (repriced to $1.33).
- Repricing executive options can be viewed as rewarding management despite poor shareholder returns.
📋 Key Facts
- Three directors (David E.I. Pyott, Katharine Knobil, and Suzanne Bruhn) are retiring or not standing for reelection at the 2026 Annual Meeting.
- Stock options granted on or before March 1, 2025, were repriced to $1.33 per share, the closing price on April 17, 2026.
- The repricing applies to all employees, including CEO Bernard Coulie, CFO Keith Cummings, CHRO Lily Cheung, and COO Minnie Kuo.
- Executive leadership must remain with the company for an 18-month retention period to benefit from the repriced exercise price.
- The board stated that all employee options were 'underwater' prior to this action.
Pliant Therapeutics has established a new $50.0 million at-the-market (ATM) offering program with Leerink Partners LLC and terminated its previous, unused 2021 sales agreement with Cantor Fitzgerald.
🚩 Red Flags
- Potential for $50 million in shareholder dilution through the new ATM facility.
📋 Key Facts
- Entered into a 2026 Sales Agreement with Leerink Partners LLC for an ATM offering of up to $50.0 million.
- Terminated the 2021 Sales Agreement with Cantor Fitzgerald & Co. effective March 27, 2026.
- No shares were sold under the 2021 Sales Agreement prior to its termination.
- The company incurred no termination penalties for ending the 2021 agreement.
Pliant Therapeutics announced its financial results for the fourth quarter ended December 31, 2025. The filing serves as a formal disclosure of the company's year-end performance via a furnished press release.
📋 Key Facts
- Reported financial results for the fourth quarter ended December 31, 2025, on March 11, 2026.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition).
- Exhibit 99.1 contains the detailed press release regarding the financial results.
- The report was signed by Keith Cummings, M.D., MBA, Chief Financial Officer.
Pliant Therapeutics, Inc. has amended its Stockholder Rights Agreement to extend the expiration date of its 'poison pill' by one year. The amendment moves the final expiration time from March 11, 2026, to March 11, 2027.
🚩 Red Flags
- Extension of defensive 'poison pill' measures can be viewed as management entrenchment.
- Multiple 8-K items (1.01 and 3.03) triggered by a single event.
📋 Key Facts
- The Amendment to Stockholder Rights Agreement was entered into on March 3, 2026, with Computershare Trust Company, N.A.
- The original Rights Agreement was dated March 12, 2025.
- The expiration date is extended from March 11, 2026, to March 11, 2027, at 5:00 p.m. New York City time.
- The stated purpose is to prevent an entity from gaining control through open market accumulation without paying a control premium.
- The company stated the amendment was not in response to any specific takeover offer.
Pliant Therapeutics, Inc. announced the appointment of Minnie Kuo as Chief Operating Officer, effective December 10, 2025. Ms. Kuo transitions from her previous role as the company's Chief Development Officer.
📋 Key Facts
- Minnie Kuo appointed as Chief Operating Officer (COO) effective December 10, 2025.
- Ms. Kuo previously served as the Company's Chief Development Officer since September 2023.
- No additional compensation was provided to Ms. Kuo for this new appointment.
- Ms. Kuo brings over 20 years of experience from companies including Vir Biotechnology, Nektar Therapeutics, Gilead Sciences, and Roche/Genentech.
Pliant Therapeutics, Inc. announced the termination of Chief Medical Officer Éric Lefebvre, M.D., effective December 15, 2025. The company intends to retain Dr. Lefebvre as a consultant post-separation to facilitate the transition of his responsibilities.
🚩 Red Flags
- Involuntary termination of a key C-suite executive (CMO) in a clinical-stage biotech company can signal internal friction or shifts in clinical strategy.
- The departure is effective mid-month, suggesting an immediate transition period.
📋 Key Facts
- Chief Medical Officer Éric Lefebvre, M.D. will terminate employment on December 15, 2025.
- The departure was initiated by the Company (notified the officer).
- Dr. Lefebvre will transition to a consulting role after his separation date to support responsibility handover.
Pliant Therapeutics, Inc. filed an 8-K to furnish its third quarter 2025 financial results press release for the period ended September 30, 2025.
📋 Key Facts
- The filing was made on November 6, 2025.
- The report pertains to the third quarter ended September 30, 2025.
- The company is reporting under Item 2.02 (Results of Operations and Financial Condition).
- Financial results were released via a press release dated November 6, 2025.
Pliant Therapeutics, Inc. announced the resignation of Hans Hull from his position as Chief Business Officer, effective October 20, 2025. The company stated that the departure was not due to any disagreement regarding operations, policies, or practices.
🚩 Red Flags
- Sudden departure of a C-suite officer (Chief Business Officer) can sometimes signal internal shifts, though not explicitly indicated here.
📋 Key Facts
- Hans Hull resigned as Chief Business Officer on October 20, 2025.
- The resignation is effective immediately as of the date reported.
- The company explicitly stated there was no disagreement with management regarding operations, policies, or practices.
Pliant Therapeutics, Inc. has fully repaid and terminated its $30 million loan agreement with Oxford Finance LLC. The company made a voluntary prepayment of $32.4 million to satisfy all outstanding principal, interest, and fees.
🚩 Red Flags
- The high cost of prepayment ($2.4 million over the $30 million principal) reflects significant interest/fees accrued during the term.
📋 Key Facts
- Completed voluntary prepayment of $32.4 million on October 14, 2025.
- The payoff amount covers all outstanding principal, accrued/unpaid interest, fees, costs, and expenses.
- The original loan agreement was dated March 11, 2024, with Oxford Finance LLC as collateral agent.
- Original facility allowed for up to $150 million in term loans; the company had utilized $30 million of that capacity.
- Repayment effectively terminates all obligations and liabilities under the Loan Agreement.
Pliant Therapeutics, Inc. filed an 8-K to furnish its second quarter 2025 financial results press release. The filing is a standard earnings announcement and does not contain material changes in corporate structure or unexpected financial distress.
📋 Key Facts
- The company announced financial results for the second quarter ended June 30, 2025.
- The report was filed on August 7, 2025.
- The filing includes a press release as Exhibit 99.1.
Pliant Therapeutics held its Annual Meeting of Stockholders on June 5, 2025. The meeting resulted in the election of three Class II directors and the approval of several shareholder proposals, including an amendment to limit officer liability.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual Meeting held on June 5, 2025.
- Approved election of John Curnutte, M.D., Ph.D., Katharine Knobil, M.D., and Thomas McCourt as Class II directors to serve until the 2028 Annual Meeting.
- Approved an amendment to the Certificate of Incorporation to limit the liability of certain officers under Delaware law (Proposal No. 3).
- Ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Approved non-binding advisory compensation for named executive officers (Say-on-Pay).
- Total common stock outstanding at record date (April 9, 2025) was 61,386,278 shares.
Pliant Therapeutics, Inc. filed an 8-K to furnish its quarterly earnings press release for the first quarter ended March 31, 2025.
📋 Key Facts
- The filing is a routine announcement of Q1 2025 financial results.
- The report was issued on May 8, 2025.
- The company's CFO, Keith Cummings, signed the report.
Pliant Therapeutics announced a significant workforce reduction impacting approximately 45% of its employees and the termination of its Chief Legal and Compliance Officer. The company expects to incur $3.6 million in severance-related charges by the end of Q2 2025.
🚩 Red Flags
- Massive workforce reduction (45% of staff) often indicates severe liquidity constraints or a pivot in business strategy.
- Departure of the Chief Legal and Compliance Officer during a restructuring period is a high-risk indicator for governance/compliance stability.
- Significant cash outflow ($3.6M) expected in the immediate quarter.
📋 Key Facts
- Workforce reduction impacts ~45% of current employees.
- Estimated one-time termination benefits/severance costs: $3.6 million.
- Reduction in force expected to be substantially complete by the end of Q2 2025.
- Mike Ouimette, Chief Legal and Compliance Officer and Corporate Secretary, terminated effective May 1, 2025.
Pliant Therapeutics, Inc. has adopted a shareholder rights plan (commonly known as a 'poison pill') in response to recent accumulations of common stock. The plan is designed to prevent any entity from gaining control without paying an appropriate premium or allowing the Board sufficient time to evaluate alternatives.
🚩 Red Flags
- Adoption of a 'poison pill' typically indicates an active or perceived hostile takeover attempt or significant accumulation by an activist investor.
- Potential for extreme dilution to existing shareholders if a Flip-in event is triggered (Rights allow purchase of stock at 2x the exercise price).
- The plan specifically mentions recent accumulations of Common Stock as the catalyst.
📋 Key Facts
- Board adopted a stockholder rights agreement on March 12, 2025.
- Dividend of one Right for each outstanding share of Common Stock to stockholders of record as of March 25, 2025.
- Exercise price is $12.64 per Right to purchase 1/1000th of a share of Series A Junior Participating Preferred Stock.
- The plan includes 'Flip-in' and 'Flip-over' provisions triggered by an 'Acquiring Person'.
- An 'Acquiring Person' is defined as owning 20% or more for passive investors, or 10% or more for non-passive investors.
- The Rights expire on March 11, 2026, unless redeemed or triggered earlier.
Pliant Therapeutics, Inc. issued an 8-K to announce its financial results for the fourth quarter ended December 31, 2024.
📋 Key Facts
- Report date: March 3, 2025
- Reporting period: Fourth quarter ended December 31, 2024
- The filing includes a press release as Exhibit 99.1 regarding financial results.
Pliant Therapeutics is assembling an outside expert panel to review unblinded data for its BEACON-IPF Phase 2b trial of bexotegrast following a recommendation from the Data Safety Monitoring Board (DSMB). This move follows clinical developments in patients with idiopathic pulmonary fibrosis.
🚩 Red Flags
- Unblinded data review by an outside panel often suggests a potential safety concern or efficacy issue that requires specialized adjudication, which can lead to clinical holds or trial termination.
📋 Key Facts
- The Company is initiating an assembly of an outside expert panel to review unblinded data.
- The review pertains to the BEACON-IPF Phase 2b trial of bexotegrast.
- The action was taken per the charter of the trial's independent Data Safety Monitoring Board (DSMB).
- The trial targets patients with idiopathic pulmonary fibrosis (IPF).
Pliant Therapeutics has voluntarily paused enrollment and dosing in its Phase 2b BEACON-IPF trial of bexotegrast for idiopathic pulmonary fibrosis. The decision follows a data review and recommendations from the trial's independent Data Safety Monitoring Board (DSMB).
🚩 Red Flags
- Clinical trial pause in a Phase 2b/3 program is a significant risk factor for biotech companies, potentially indicating safety concerns or lack of efficacy.
- The involvement of the DSMB suggests the decision was driven by external oversight rather than purely internal management discretion.
📋 Key Facts
- Trial Name: BEACON-IPF (Phase 2b/3)
- Drug Candidate: bexotegrast
- Indication: Idiopathic pulmonary fibrosis (IPF)
- Action: Voluntary pause of enrollment and dosing
- Trigger: Recommendations from the independent Data Safety Monitoring Board (DSMB) following a prespecified data review
- Effective Date of Event: February 7, 2025
Pliant Therapeutics, Inc. filed an 8-K to furnish its third quarter financial results for the period ended September 30, 2024.
📋 Key Facts
- Report date: November 7, 2024
- Reporting period: Third Quarter ended September 30, 2024
- The filing serves to furnish the press release containing financial results (Exhibit 99.1).
Pliant Therapeutics, Inc. has amended and restated its Bylaws to align with Delaware law and update stockholder nomination procedures.
📋 Key Facts
- The Board of Directors approved the 'Third Amended and Restated Bylaws' on September 24, 2024.
- Amendments include alignment with recent Delaware law developments and jurisprudence.
- Changes involve revising procedural and disclosure requirements for stockholder director nominations and proposals.
- Includes a new provision regarding severability and other ministerial/conforming changes.
Pliant Therapeutics, Inc. filed an 8-K to furnish its second quarter 2024 financial results for the period ended June 30, 2024.
📋 Key Facts
- Report date: August 7, 2024
- Reporting period: Second Quarter ended June 30, 2024
- The filing serves to furnish a press release containing financial results (Exhibit 99.1).
Pliant Therapeutics announced positive 24-week data from its Phase 2a INTEGRIS-PSC clinical trial for bexotegrast. The study met its primary safety endpoint, demonstrating the drug was well tolerated in patients with primary sclerosing cholangitis.
📋 Key Facts
- Trial: INTEGRIS-PSC (Phase 2a, multinational, randomized, double-blind, placebo-controlled).
- Cohort: 320 mg dose group.
- Primary Endpoint Met: Safety demonstrated; bexotegrast was well tolerated up to 40 weeks of treatment.
- Clinical Observations: Pruritus and cholangitis occurred at lower proportions in the bexotegrast group compared to placebo.
- Indication: Primary sclerosing cholangitis (PSC) with suspected moderate to severe liver fibrosis.
Pliant Therapeutics held its Annual Meeting of Stockholders on June 13, 2024. The meeting resulted in the election of three Class I directors and the ratification of Deloitte & Touche LLP as independent auditors, but notably, shareholders failed to approve a non-binding advisory vote on executive compensation.
🚩 Red Flags
- Failure of 'Say-on-Pay' proposal: Shareholders voted against the compensation of named executive officers, indicating potential dissatisfaction with management incentives or pay structures.
📋 Key Facts
- Annual Meeting held on June 13, 2024.
- Steve Krognes appointed to the Board and named Chairperson of the Audit Committee.
- Class I directors Hoyoung Huh, Darren Cline, and David Pyott were elected for three-year terms ending in 2027.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for fiscal year 2024.
- Shareholders voted against Proposal 2 (Say-on-Pay), which was a non-binding advisory vote on executive compensation.
Pliant Therapeutics announced positive topline data from a 12-week Phase 2a clinical trial of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (IPF). The study utilized PET imaging to demonstrate reduced total lung collagen in treated patients compared to an increase in the placebo group.
📋 Key Facts
- Trial Design: 12-week, randomized, double-blind, placebo-controlled trial conducted at Massachusetts General Hospital.
- Primary Endpoint Result: Bexotegrast-treated patients showed reduced total lung collagen via PET imaging; placebo group showed increased collagen.
- Secondary Endpoints: Improvements in forced vital capacity and reduction in cough severity across all timepoints compared to placebo.
- Safety Profile: Bexotegrast 160 mg was well tolerated with no drug-related serious adverse events (SAEs) or discontinuations reported.
Pliant Therapeutics, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2024.
📋 Key Facts
- Reporting period: First Quarter ended March 31, 2024.
- Filing date: May 6, 2024.
- The filing includes a press release (Exhibit 99.1) detailing the company's financial condition and results of operations.
Pliant Therapeutics entered into an Amended and Restated Loan and Security Agreement on March 11, 2024, securing up to $150 million in term loans. The company drew an initial $30 million on the effective date to fund working capital and general business requirements.
🚩 Red Flags
- Significant debt load ($150M potential) used primarily for working capital and general business requirements.
- Negative pledge on substantially all intellectual property, which is the primary value driver for a biotech company.
- Default interest rate penalty of 5% above applicable rate in event of default.
📋 Key Facts
- Entered into Amended and Restated Loan and Security Agreement with Oxford Finance LLC (Agent) and various Lenders on March 11, 2024.
- Aggregate principal amount of Term Loans up to $150.0 million ($50.0 million subject to Lender discretion).
- Initial drawdown of $30.0 million on the effective date (includes $10.0 million previously outstanding).
- Optionality to borrow an additional $70.0 million contingent upon bexotegrast development milestones.
- Interest rate: Floating rate = greater of (1-month SOFR + 3.50%) or (5.25%).
- Repayment schedule begins July 1, 2028, with a final maturity date of March 1, 2029 (extendable to 2030).
- Collateral: Substantially all company assets, including a negative pledge on intellectual property.
- Announced implementation of BEACON-IPF as an adaptive Phase 2b/3 trial for bexotegrast in IPF patients.
Pliant Therapeutics, Inc. filed an 8-K to furnish its press release announcing financial results for the fourth quarter ended December 31, 2023.
📋 Key Facts
- Reporting period: Fourth quarter ended December 31, 2023.
- Filing date: February 27, 2024.
- The filing includes Exhibit 99.1 containing the earnings press release.
Pliant Therapeutics announced positive 12-week interim data from its Phase 2a INTEGRIS-PSC clinical trial for bexotegrast. The 320 mg dose group met primary and secondary endpoints, demonstrating safety and exploratory efficacy in reducing liver fibrosis markers.
📋 Key Facts
- Interim data released on February 4, 2024, from the INTEGRIS-PSC Phase 2a trial.
- The 320 mg dose group met primary and secondary endpoints regarding safety and tolerability.
- Exploratory efficacy endpoints showed reduction in ELF score and PRO-C3 levels relative to placebo at Week 12.
- Bexotegrast-treated patients showed stabilization of alkaline phosphatase (ALP) levels compared to an increase in the placebo group.
- MRI imaging indicated improved hepatocyte function and bile flow in the treatment group.